drugset / Trial / NCT03595683
Pembrolizumab and EDP1503 in Advanced Melanoma
Phase 2
Terminated
8 enrolled
University of Chicago
Evelo Biosciences, Inc. · collabMerck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma. The study will involve initial administration of EDP1503 for a run-in period (2 weeks) followed by administration of both EDP1503 (twice daily) and pembrolizumab (every 3 weeks). Mandatory biopsies are required before starting study treatment and after 2 weeks of EDP1503 dosing.
Timeline
- Start
- 2018-10-02
- Primary completion
- 2025-07-31
- Completion
- 2025-07-31
Outcome
Outcome not reported
Stopped: “Drug supply no longer available.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDP1503 | Other / unclassified | 7.5e+10 unknown | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |